Analysis of Pre-Exposure Prophylaxis Utilization in a Medicaid Population

Monday, May 10, 2021
Warren Smith, PharmD
Commonwealth Medicine
Mckenzie Taylor, PharmD
Commonwealth Medicine
Thomas Pomfret, PharmD, MPH, BCPS
Commonwealth Medicine
Stephanie Tran, PharmD
University of Massachusetts Medical School
Pavel Lavitas, PharmD, BCPS
Commonwealth Medicine
Caroline J. Alper, MD
Commonwealth Medicine
Mark Tesell, PharmD, BCPS
Commonwealth Medicine
Karen Clements, ScD
Commonwealth Medicine
Kimberly Lenz, PharmD
Commonwealth Medicine

Approximately two million new cases of human immunodeficiency virus (HIV) infection occur every year. Adhering to a pre-exposure prophylaxis therapy(PrEP) allows patients to reduce their risk of transmission by about 90%, but adherence to the therapy can vary a great deal. This presentation evaluates the utilization of two PrEP therapies, emtricitabine/tenofovir disoproxil fumarate (Truvada®) and emtricitabine/tenofovir alafenamide (Descovy®), among a MassHealth population.